These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20636022)

  • 41. Second-generation vaccines against leishmaniasis.
    Coler RN; Reed SG
    Trends Parasitol; 2005 May; 21(5):244-9. PubMed ID: 15837614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A historical review of the role of cytokines involved in leishmaniasis.
    Mirzaei A; Maleki M; Masoumi E; Maspi N
    Cytokine; 2021 Sep; 145():155297. PubMed ID: 32972825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo evaluation of immune responses in leishmaniasis: the use of cross-species leishmanin preparations for skin testing.
    Akuffo H; Darce M; Maasho K; Berhan TY
    Am J Trop Med Hyg; 1995 Jul; 53(1):16-22. PubMed ID: 7625529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis.
    Bottrel RL; Dutra WO; Martins FA; Gontijo B; Carvalho E; Barral-Netto M; Barral A; Almeida RP; Mayrink W; Locksley R; Gollob KJ
    Infect Immun; 2001 May; 69(5):3232-9. PubMed ID: 11292745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK; Naskar K; De T
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration.
    Musa AM; Noazin S; Khalil EA; Modabber F
    Trans R Soc Trop Med Hyg; 2010 Jan; 104(1):1-2. PubMed ID: 19712953
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Montenegro's skin reactions and antibodies against different Leishmania species in dogs from a visceral leishmaniosis endemic area.
    Baleeiro CO; Paranhos-Silva M; dos Santos JC; Oliveira GG; Nascimento EG; de Carvalho LP; dos-Santos WL
    Vet Parasitol; 2006 Jun; 139(1-3):21-8. PubMed ID: 16567046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Leishmaniasis.
    Kedzierski L
    Hum Vaccin; 2011 Nov; 7(11):1204-14. PubMed ID: 22048116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cutaneous leishmaniasis: progress towards a vaccine.
    Launois P; Tacchini-Cottier F; Kieny MP
    Expert Rev Vaccines; 2008 Oct; 7(8):1277-87. PubMed ID: 18844599
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Applications of molecular methods for Leishmania control.
    Singh S; Dey A; Sivakumar R
    Expert Rev Mol Diagn; 2005 Mar; 5(2):251-65. PubMed ID: 15833054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular basis of Trypanosoma cruzi and Leishmania interaction with their host(s): exploitation of immune and defense mechanisms by the parasite leading to persistence and chronicity, features reminiscent of immune system evasion strategies in cancer diseases.
    Ouaissi A; Ouaissi M
    Arch Immunol Ther Exp (Warsz); 2005; 53(2):102-14. PubMed ID: 15928579
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cutaneous leishmaniasis: disease susceptibility and pharmacogenetic implications.
    Ameen M
    Pharmacogenomics; 2009 Mar; 10(3):451-61. PubMed ID: 19290793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic vaccines for leishmaniasis.
    Khamesipour A
    Expert Opin Biol Ther; 2014 Nov; 14(11):1641-9. PubMed ID: 25077737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Leishmaniasis in humans: drug or vaccine therapy?
    Ghorbani M; Farhoudi R
    Drug Des Devel Ther; 2018; 12():25-40. PubMed ID: 29317800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccine for prophylaxis and immunotherapy, Brazil.
    Genaro O; de Toledo VP; da Costa CA; Hermeto MV; Afonso LC; Mayrink W
    Clin Dermatol; 1996; 14(5):503-12. PubMed ID: 8889328
    [No Abstract]   [Full Text] [Related]  

  • 59. Leishmaniasis and various immunotherapeutic approaches.
    Taslimi Y; Zahedifard F; Rafati S
    Parasitology; 2018 Apr; 145(4):497-507. PubMed ID: 27974063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Imaging of the host/parasite interplay in cutaneous leishmaniasis.
    Millington OR; Myburgh E; Mottram JC; Alexander J
    Exp Parasitol; 2010 Nov; 126(3):310-7. PubMed ID: 20501336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.